Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Increase in Short Interest

Key Points

• Pharming Group N.V. experienced a substantial increase in short interest, rising by 378.6% from 1,400 to 6,700 shares between August 15 and August 31.
• A hedge fund, Silverberg Bernstein Capital Management LLC, raised its stake in Pharming Group by 8.6% during the second quarter, owning approximately 0.08% of the company after adding shares.
• Pharming Group reported a profit of $0.06 EPS for the last quarter, exceeding expectations, and generated $93.20 million in revenue compared to analysts' forecasts of $70.36 million.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) was the recipient of a large growth in short interest in the month of August. As of August 31st, there was short interest totaling 6,700 shares, a growth of 378.6% from the August 15th total of 1,400 shares. Approximately 0.0% of the company's shares are short sold. Based on an average trading volume of 8,000 shares, the short-interest ratio is currently 0.8 days. Based on an average trading volume of 8,000 shares, the short-interest ratio is currently 0.8 days. Approximately 0.0% of the company's shares are short sold.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC raised its stake in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) by 8.6% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 52,147 shares of the company's stock after purchasing an additional 4,150 shares during the quarter. Silverberg Bernstein Capital Management LLC owned about 0.08% of Pharming Group worth $557,000 at the end of the most recent quarter. 0.03% of the stock is currently owned by institutional investors and hedge funds.

Pharming Group Stock Up 9.5%

PHAR stock opened at $14.80 on Friday. The stock has a market capitalization of $1.01 billion, a P/E ratio of -113.85 and a beta of 0.05. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.07 and a current ratio of 2.79. Pharming Group has a one year low of $7.10 and a one year high of $17.08. The company has a 50 day moving average price of $12.00 and a two-hundred day moving average price of $10.33.

Pharming Group (NASDAQ:PHAR - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.16. The firm had revenue of $93.20 million during the quarter, compared to analysts' expectations of $70.36 million. Pharming Group had a negative net margin of 2.19% and a negative return on equity of 3.31%. Pharming Group has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Pharming Group will post -0.2 EPS for the current year.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.